| INTRODUCTION
Post-translational modifications (PTMs) are essential mechanisms that eukaryotic cells use to diversify their protein functions and coordinate their signaling networks. 1 Defects in PTMs have been linked to numerous developmental disorders and human diseases, highlighting the importance of PTMs in maintaining normal cellular states. In this study, we report on 3 clinically undiagnosed patients from 2 families (2 males, 1 female). Clinical features included developmental and speech delay combined with dysmorphic features and skeletal defects. Sequence analysis revealed 2 novel homozygous variants in the PRMT7 gene, encoding a member of the protein arginine Nmethyltransferase (PRMTs) family of proteins. 2 PRMTs are enzymes that direct post-translational methylation on targeted arginine residues in eukaryotes and regulate several cellular processes including signal transduction, RNA processing, DNA repair, protein subcellular localization and interactions. 3, 4 Among the PRMTs, that generate dimethylarginine, PRMT7 is unique in producing exclusively monomethylarginine products and appears to participate in broad cellular processes under normal and disease conditions, including cancer. 5 Transcriptome analysis of skeletal muscle from wild-type and Prmt7-null mice, showed that 130 distinctive genes involved in skeletal and muscular disorders displayed altered expression in the absence of Prmt7. 6 In addition, PRMT7 plays a role in maintaining the embryonic stem cell stemness 7 and negatively regulates the neuronal differentiation. 8 Germline PRMT7 mutations were originally described by Akawi et al in 6 females from 3 families with a novel syndromic intellectual disability condition, characterized by mild intellectual disability, facial dysmorphisms, microcephaly, short stature and brachydactyly. 9 More recently, a male child with severe intellectual disability, seizures and microcephaly, was reported displaying a homozygous deletion encompassing the transcription start site of PRMT7 producing a null allele. 10 This disorder is now known as SBIDDS syndrome (Short stature, Brachydactyly, Intellectual Developmental Disability, and Seizures) (OMIM 617157).
The patients reported in this study extend the clinical and muta- 
| PATIENTS AND METHODS

| Family 1
The patient (patient 1) ( Figure 1A , 1a-b), a male, was the second child of Italian consanguineous parents (first cousins). A diagnosis of intrauterine growth retardation was made at the 22nd week of gestation. 
| Case 2
This 15-year-old female (patient 3) ( Figure 1A 
| Genetic studies
See Appendices S1 and S2 (Supporting information).
3 | RESULTS
| Family 1
SNP-array analysis in patient 1 identified several long contiguous stretches of homozygosity all over the genome (7.63% of the autosomal genetic material), consistent with a third degree consanguinity and displayed a small microduplication on the long arm of a chromosome 12 (ISCN: arr 12q24.23(118 287 778-118 590 408)×3) which was inherited from the father. Targeted exome sequencing data analysis (Tables S1 and S2) , revealed a homozygous private nonsense change, NM_019023.2:c.322G>T, p.(Glu108Ter), in exon 4 of the PRMT7 gene ( Figure 1B ). The unaffected parents and the older brother were heterozygous for this mutation.
| Family 2
Karyotype and high-resolution CGH-array analysis (244 K; Agilent
Technologies, Waldbronn, Germany) in patients 2 and 3 were normal. The clinical characteristics of our patients and those previously published are reported in Table 1 . All known patients share global developmental and speech delay, although with a variable degree of expression. Severe/moderate intellectual disability was found in our patients as well as in the case reported by Kernohan et al, while mild developmental delay was found in the first reported families. 9 It is possible that the degree of clinical expression is related to specific mutations. In the present series, we hypothesize that the more severe phenotype in family 1 in comparison to that observed in family 2 might be caused by a more deleterious mutation. Indeed, the PRMT7 nonsense mutation of Skeletal anomalies are considered a distinct marker of the syndrome together with the neurological involvement. 12 and reduced through the methylation of disheveled homolog 3 (DVL3) by the same PRMTs. 13 Interestingly, whole-body protein arginine methyltransferase Prmt7 −/− mice, display growth retardation, skeletal defects, brachydactyly of the fifth metatarsal bone and reduced bone mineral content. These features are particularly evident in the patient 1. In addition, Prmt7 −/− mice has a significant reduction in muscle stem cells function, leading to defects in regenerative capacity upon muscle injury. 6 This cell-intrinsic mechanism could contribute to the hypotonia observed in SBIDDS patients, whose expressivity is likely dependent on the PRMT7 genotype, and more specifically the presence of null alleles might be associated to a more severe decrease in skeletal muscle tone. This could explain also the feeding difficulties of patient 1 that are generally observed in infants with severe hypotonia.
Early diagnosis of the disease and genotype-phenotype correlation can provide the opportunity to establish coordinated multispecialty management of the patient, focusing on the changing issues through childhood, including anticipatory care for developmental disabilities, orthopedic problems, feeding, and growth difficulties. Further studies are required to delineate the natural history of this disorder.
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